| First Author | Brubaker PL | Year | 2010 |
| Journal | Endocrinology | Volume | 151 |
| Issue | 5 | Pages | 1984-9 |
| PubMed ID | 20305008 | Mgi Jnum | J:159985 |
| Mgi Id | MGI:4453237 | Doi | 10.1210/en.2010-0115 |
| Citation | Brubaker PL (2010) Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151(5):1984-9 |
| abstractText | The incretin hormone, glucagon-like peptide-1 (GLP-1), is now being used in the clinic to enhance insulin secretion and reduce body weight in patients with type 2 diabetes. Although much is already known about the biology of GLP-1, much remains to be understood. Hence, this review will consider recent findings related to the potential for enhancing endogenous levels of GLP-1 through selective use of secretagogues and the beneficial cardiovascular, neuroprotective, and immunomodulatory effects of GLP-1, as well as the possible effects of GLP-1 to enhance beta-cell growth and/or to induce pancreatitis or thyroid cancer. Finally, the potential for molecular medicine to enhance the success of GLP-1 therapy in the clinic is considered. A better understanding of the fundamental biology of GLP-1 may lead to new therapeutic modalities for the clinical use of this intestinal hormone. |
